MCC-555 Mitsubishi-Tokyo pharmaceuticals

IDrugs

Volumn 4, Issue 5, 2001, Pages 586-589

  Velussi, Mario ^a  

^a Monfalcone and Gorizia Diabetology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646779132     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Synthesis and SAR study of 5-{6-alkoxy-2-naphthalenyl)methyl2,4-thiazolidine-dione derivative as potent antihyperglycemic agent. Ueno H, Obe T, Suehiro I, Morioka M, Ishii S, Tanaka H, Kadowaki S, Sekiya T ACS 1996 211th New Orleans MEDI 094
2. Improved insulin sensitivity in Zucker and ZDF rats following chronic treatment with novel thiazolidinedione MCC-555. Upton R, Widdowson PS, Kadowaki S, Williams G BR J PHARMACOL 1997 122 Suppl 149P Reports the action of MCC-555 in Zucker and ZDF rats.
3. MCC-555: a highly potent thiazolidinedione lacking hematological and cardiac side-effects. Ishii S, WasaW M, Ohe T, Ueno H, Tanaka H DIABETES 1996 45 Suppl 2141A Clarifies the efficacy and the lack of side effects of MCC-555.
4. The new antidiabetic drug MCC-555 ameliorates insulin resistance and acutely sensitizes insulin signaling by activation of protein synthesis. Eckel J, Tanaka H, Ishii S, Liu L DIABETES 1998 47 Suppl 1 A328
5. Mitsubishi licenses antidiabetic to J&J. PHARMA JPN 1998 1621 13
6. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor -activating properties. Reginato MJ, Bailey ST, KrakowSL, Minami C, LazarMAetalJBIOL CHEM1998 273 49 32679 32684
7. Insulin Resistance - IBC's Third International Symposium; Mechanism of Action and Novel Therapeutic Strategies, Washington DC, USA. Bums TP IDDB MEETING REPORT 1999 March 24-25 Explains the nature and function of PPARy agonists, and their use in therapeutic approaches to insulin resistance.
8. Insulin Resistance - IBC's Third International Symposium (Part II); Mechanism of Action and Novel Therapeutic Strategies, Washington DC, USA. Posner B IDDB MEETING REPORT 1999 March 24-25 Reviews the effects of MCC-555 on target tissues.
9. Novel Drug Developments for NIDDM and Insulin Resistance IBC Conference London, UK. Bums T IDDB MEETING REPORT 1999 April 21 Defines the potency of MCC-555.
10. The improving effect of MCC-555, an insulin sensitizer, on glucose tolerance in obese cynomolgus monkeys. Ishii S, Hike N, Yoshida T ANN MEET AM DIABETES ASSOC1999 59 Abs 2006
11. Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones. Lohray BB, Bhushan V, Reddy AS, Rao PB, Reddy NJ, Harikishore P, Haritha N, Vikramaditiyan RK, Chakrabarti R, Rajagopalan R, Katneni K J MED CHEM 1999 42 14 2569 2581
12. The thiazolidinedione, MCC-555, reduces OB expression in mature adipocytes, but does not alter plasma leptin concentrations. Widdowson PS, Upton R, Ishii S, Williams G BR J PHARMACOL 1998 123 Proc Suppl 187P MCC-555 reduces OB expression, with no leptin modification.
13. The thiazolidinedione, MCC-555, prevents nitric oxide synthase induction in the pancreas of the Zucker diabetic fatty rat Pickavance LC, Widdowson PS, Foster JR, Ishii S BRJ PHARMACOL 1999128 Proc Suppl 116P
14. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Liu LS et al ENDOCRINOLOGY 1998139114531 -4539 Action of MCC-555 on Isolated cardiomyocytes.
15. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. Pickavance L, Widdowson PS, King P, Ishii S, Tanaka H, Williams G BR J PHARMACOL 1998125 4 767 - 770
16. Synthesis and biological activity of novel thiazolidinediones. Prabhakar C et al BIOORG MED CHEM LETT 1998 8 19 2725 - 2730 Clarifies the characteristics of these novel thiazolidinediones.
17. Therapeutic approaches to insulin resistance. Laight DW EXP OP/NTHERR4T20001011 1703-1709 Explains the nature and function of PPARy agonists, and their use in therapeutic approaches to insulin resistance.
18. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferates. Corton JC, Andersen SP, Stauber A ANN REV PHARMACOL TOXICOL 2000 40 491 - 518
19. Acute effect of MCC-555 in isolated hepatocytes of Otsuka LongEvans Tokushima Fatty rats. Mizubayashi R, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori H, Kiriyama T, Kasuya Y, Yasuda Y, Hotta N DIABETOLOGIA 2000 43 Suppl 1 A190 Explains the action of MCC-555 on hepatocytes.
20. Mechanism of troglhazone action in type 2 diabetes. Petersen KF, Krssak M, Inzucchi S. Cline GW, Dufour S, Shulman GT DIABETES 2000 49 5 827-831
21. Open-label extension studies in type 2 diabetic patients. Fonseca V, Foyt HL, Shen K, Whitcomb R DIABETES 2000 23 3 354-359
22. Metabolic effects of troglKazone therapy in type 2 diabetic, obese and lean normal subjects. Prias JP, Yu JG, Kruszynska YT, Olefsky JM DIABETES CARE 2000 23 1 64-69
23. Troglitazone induces expression of PPARy liver. Davies GF, Khandelwal RL, Roesler WJ MOL CELL BIOL RES COMMUN 1999 2 3 202208
24. Troglitazone-induced fulminant hepatitis. Report of a case with autopsy findings. Li H, Heller DS, Leevy CB, Zierer KG, Klein KM J DIABETES COMPLICATIONS200Q143 175-177
25. Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Murphy EJ, Davem TJ, Shakil AO, Schick L, Masharani U, Chow H, Preise C, Lee WM, Bass WM DIG DIS SCI 2000 45 3 549-553
26. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Fukano M, Amano S, Sato J, Yamamoto K, Adachi H, Okabe H, Fujiama Y, Bamba T Hum Path 2000 31 2 250-253
27. Troglitazone and emerging glhazones: new avenues for potential therapeutic benefits beyond glycémie control. Horikoshi H, Hashimoto T, Fujiwara T PROG DRUG RES 2000 54 191-212
28. Rosiglitazone: a new therapy for Type 2 diabetes. Greene DA EXP OPIN INVEST DRUGS 1999 8 10 1709-1719
29. Rosiglitazone. Goldstein BJINTJ CLIN PRACT2000 54 5 333-337
30. Absorption, disposition, and metabolism of rostglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Cox PJ, Ryan DA, Mollis FJ, Harris AM, Miller AK, Vousden M, Cowley H DRUG METAB DISPOS 2000 174287-294
31. Rosiglitazone taken once daily provides effective grycaemic control in patients with type 2 diabetes mellrtus. Nolan JJ, Jones NP, Pathwardhan R, Deacon LF DIABETIC MED 2000174 287-294
32. Rosiglitazone short-term lowers fasting and post-prandial glucose in patients with type II diabetes. Raskin P, Rappaport EB, Cole ST. Yan Y, Patwardhan R, Freed Ml DIABETOLOGIA 2000 43 3 278-284
33. Naphthalene derivatives. Ueno H, Oe T, Suehiro I, Nakamura F MITSUBISHI-TOKYO PHARMACEUTICALS EP-00604983 1996
34. Mitsubishi Chemical. ING Barings ANALYST REPORT 1999 February 12